Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
NCT02691780
·
clinicaltrials.gov ↗
NA
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
not enrolled
Conditions
Refractory Solid Tumors
Interventions
DRUG:
Sorafenib
Sponsor
Samsung Medical Center